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The DNA hypomethylating agents decitabine and 5-azacytidine are the only two drugs approved for
treatment of all subtypes of the myeloid malignancy myelodysplastic syndromes (MDS). the key to drug
activity is incorporation into target cell DNA, however, a practical method to measure this incorporation
is un-available. Here, we report a sensitive and specific LC-MS/MS method to simultaneously measure
decitabine incorporation and DNA hypomethylation. A stable heavy isotope of 2'-deoxycytidine was
used as an internal standard and one-step multi-enzyme digestion was used to release the DNA bound
drug. Enzyme-released decitabine along with other mononucleosides were separated by a reversephase C18 column and quantified by mass spectrometry using multiple-reaction-monitoring (MRM)
mode, with a lower limit of quantitation at 1.00 nM. In vitro studies demonstrated dosage and timedependent incorporation of decitabine into myeloid leukemia cell DNA that correlated with extent of
DNA hypomethylation. When applied to clinical samples serially collected from MDS patients treated
with decitabine, the method again demonstrated correlation between decitabine DNA-incorporation
and DNA hypomethylation. This novel assay to measure the intended molecular pharmacodynamic
effect of decitabine therapy can therefore potentially provide insights into mechanisms underlying
sensitivity versus resistance to therapy.

Decitabine (5-aza-2'-deoxycytidine) is a nucleoside analog of 2'-deoxycytidine. Decitabine was introduced clinically four decades ago and was approved for the treatment of patients with myelodysplastic syndrome (MDS) in
2006 in the USA1-4. The only other drug approved to treat all subtypes of MDS is 5-azacytidine which is reduced
in cells to the same active molecule, decitabine triphosphate, as decitabine. After parenteral administration, decitabine undergoes a three-step phosphorylation within cells into its active metabolite, decitabine triphosphate [first,
to its monophosphate by deoxycytidine kinase (DCK); then to its diphosphate by deoxycytidine monophosphokinase; and finally to its triphosphate by nucleoside diphosphokinase] which is then directly incorporated by DNA
polymerases into DNA during the S-phase of replication5. Decitabine triphosphate is the primary intracellular
metabolite that has the antileukemic effect both in vivo and in vitro. Decitabine and its mono-phosphate can
be rapidly metabolized by cytidine deaminase (CDA) and deoxycytidine deaminase (DCTD) respectively into
uridine derivatives that do not have an epigenetic therapeutic effect6. After incorporation into DNA, decitabine
inhibits DNA methylation by forming a covalent bond with DNA methyltransferase 1 (DNMT1). DNMT1 is a
corepressor which generates an epigenetic repression (‘off') mark by the addition of a methyl group to the fifth
carbon of 2-deoxycytosine within the 5'-cytosine-guanosine (CpG) dinucleotides of DNA. This epigenetic mark
generated by DNMT1 is robustly linked with gene repression and aberrant repression of tumor suppressor genes
in malignant transformation7-9. Thus DNMT1-depletion by the DNA incorporated decitabine can reactivate
tumor suppressor genes, leading to terminal differentiation or apoptosis of malignant cells5,10.
Target engagement is crucial for therapeutic efficacy of any drug. Since the incorporation of decitabine into
DNA is essential for the epigenetic therapeutic effect, we postulate that quantitation of decitabine incorporation
1Department of Chemistry, Cleveland State University, 2121 Euclid Avenue, Cleveland, Ohio, 44115, USA.
2Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, 2010 East 90th Street,
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Figure 1. Schematic representation of DNA hydrolysis by a one-step tetra-enzyme digestion system that
includes DNase 1, NP 1, PDE 1, and ALP.

into cellular DNA can potentially guide individualization of therapy towards achievement of intended molecular
pharmacodynamic effects, and provide insights into sensitivity versus resistance of malignant cells, which could
be from failure to produce these intended molecular pharmacodynamic effects. Although decitabine incorporation into DNA has previously been measured using radioisotopic and liquid scintillation counting assays11,12,
these previous methods had either limited sensitivity and used radioactive isotope labeled decitabine, which is
not practical for use in clinical settings. LC-MS/MS method have been developed to quantify decitabine concentration in plasma13 however, this method is not applicable to measure decitabine incorporation in DNA and
is less sensitive to use in clinical application. Another LC-MS/MS method has been developed to quantify total
intracellular decitabine nucleotide concentrations, as well as DNA incorporation levels of decitabine14, but is less
sensitive and correlation of DNA incorporation to hypomethylation was not demonstrated.
To address this unmet need, here we developed a sensitive LC-MS/MS method to simultaneously quantify
incorporation of decitabine into DNA and DNA methylation, by measuring dG, dC, and 5mdC. The method was
applied both in vitro and in vivo. The results demonstrated that this method can quantify the incorporation of
decitabine into DNA, enabling quantification of the variation in the incorporation and response to treatment in
different models and in vivo. This assay could be a useful tool for the purpose of understanding treatment sensitivity versus resistance and provide important guidance towards an overall goal of individualizing and optimizing
therapy with this exclusive class of agent.

Results
enzymatic hydrolysis of DNA.

In this work, the DNA samples were hydrolyzed by a one-step tetra-en
zyme reaction (Fig. 1). This one-step enzyme reaction had been optimized and validated previously to retain
100% digestion efficiency in comparison to an optimized stepwise enzyme reaction15. Among the four enzymes
employed, DNase I is an endonuclease that splits phosphodiester bonds of DNA and yields oligonucleotides with
a free 3'-end hydroxyl group and a free 5'-end phosphate group; PDE I is a 3' to 5' exonuclease that successively
hydrolyzes an oligonucleotide from 5'-end to 3'-end and produce deoxynucleoside 5'-phosphate; NP1 is a 5' to 3'
exonuclease that acts in opposite direction to PDE I, and completely hydrolyzes an oligonucleotide from 3'-end
to 5'-end to produce deoxynucleoside 5'-phosphate; and ALP is a hydrolase that hydrolyzes phosphate groups
of deoxynucleotides to deoxynucleosides. Since the electrospray ionization tandem mass spectrometer (ESI-MS/
MS) used for this work had much lower limits of quantitation for deoxynucleosides than those of deoxynucleo
tides; therefore, deoxynucleosides were the sought-after products for the enzyme digestion.
Enzyme digestion efficiency was evaluated by comparing the DNA concentration calculated from the amount
of dG produced from DNA hydrolysis with the DNA concentration measured using UV spectroscopy. The rationale for the study is that DNA concentrations can be either measured by UV spectroscopy or calculated from the
amount of a nucleoside released from hydrolysis and measured by LC-MS/MS15. In this work, the concentration
of dG released from hydrolysis of calf DNA (250 mg/L measured by UV spectroscopy) of was used to calculate
the concentration of DNA using eq. 1 (see Materials and Methods section) to evaluate the enzyme digestion
efficiency. The DNA concentration (257 ± 4 mg/L, n = 5) calculated from the quantity of dG was similar to that
measured by UV (250 ± 6 mg/L, n = 5), indicating that the enzymatic hydrolysis procedure used can completely
hydrolyze DNA into individual nucleosides.

Measurement of decitabine, dG, dC and 5mdC by LC-MS/MS. The mass spectrometer was tuned by
infusion of a mixture of decitabine, dC, 5mdC, dG and IS at each concentration of 500 ng/mL in the mobile phase
to optimize both compound-dependent and source-dependent parameters. Since these deoxynucleoside were
more easily to form protonated ions than deprotonated species in the acidic mobile phase, the positive ESI was
used for the analytes' identification and quantification. As shown in Fig. 2A,C,E,G,I, the predominated precursor
ions of decitabine, dC, 5mdC, dG and IS were at m/z 229.1, 228.1, 242.0, 268.0 and 231.0, respectively. These precursor ions were broken into product ions by collision with nitrogen gas and produced the predominant product
ions at m/z 113.1, 112.1, 126.0, 152.0 and 115.0, respectively (Fig. 2B,D,F,H,J). Therefore, the mass transitions of
m/z 229.1 > 113.1, 228.1 > 112.1, 242.0 > 126.0, 268.0 > 152.0 and 231.0 > 115.0 for were chosen for the selective
quantitation of decitabine, dC, 5mdC, dG and IS by MRM mode.
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Figure 2. Representative mass spectra of precursor and product ions of decitabine, dC, 5mdC, dG and IS. (A)
the precursor ion of decitabine; (B) the major product ion of decitabine; (C) the precursor ion of dC; (D) the
major product ion of dC; (E) the precursor ion of 5mdC; (F) the major product ion of 5mdC; (G) the precursor
ion of dG; (H) the major product ion of dG; (H) the precursor ion of IS; (I) the major product ion of IS.

As shown in Fig. 3A, decitabine, dC, 5mdC and dG released by the enzyme digestion along with IS were separated and detected by our LC-MS/MS method in less than 6 min. The control studies showed that there were no
contaminations observed from free nucleosides or unincorporated decitabine when DNA was incubated with
digestion buffer without enzymes (Fig. 3B).
This method has a lower limit of quantification (LLOQ) of 1.00 nM for each analyte, which was defined by
the lowest calibrator of a calibration plot; and a linear calibration range from LLOQ to 2.00 x 103 nM (Fig. 4).
Validation of the method was done according to the US-FDA guidance for industry on bioanalytical method validation16. The inter-day and intra-day accuracy and precision of the three mixed QC concentrations were <±6%
and <8%, respectively (Table 1). The accuracy and precision of mixed calibrators over six calibration plots were
<±6% and <11%, respectively (Table 2). These data were well within the acceptance ranges of US-FDA.
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Figure 3. Representative MRM chromatograms of decitabine, dC, 5mdC, dG, and IS. (A) decitabine-treated
DNA sample incubated with tetra enzymes; (B) decitabine-treated DNA sample incubated with buffer without
tetra enzymes.

Figure 4. Calibration plots of decitabine, dC, 5mdC, and dG.
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Nominal
[Analyte] (nM)

[Decitabine] (nM)

[5mdC] (nM)

[dC] (nM)

[Measured ± SDa]

%REb

CVc

[Measured ± SDa]

%REb

CVc

1.00

0.98 ± 0.09

—2

11

0.97 ± 0.07

—3

7

4.00

4.1 ± 0.2

3

4

4.1 ± 0.2

2

20.0

20.7 ± 0.2

4

1

19.8 ± 0.5

40.0

40 ± 2

1

4

41 ± 3

200

205 ± 4

3

2

196 ± 2

—2

1

400

386 ± 1

—4

3

377 ± 2

-6

5

—1

1

—1

1

2.00 x 103

(1.97 ± 0.02) x 103

(1.98 ± 0.02) x 103

[dG] (nM)

[Measured ± SDa]

REb

CVc

[Measured ± SDa]

%REb

CVc

1.02 ± 0.06

2

6

0.97 ± 0.07

—3

7

4

3.9 ± 0.2

3

5

4.1 ± 0.2

3

5

—1

3

22 ± 1

10

5

19.6 ± 0.2

—2

1

3

7

42 ± 3

6

6

39 ± 1

—3

2

194 ± 3

—3

8

203 ± 8

2

4

407 ± 1

2

2

412 ± 1

3

3

—0.4

3

1

1

(1.99 ± 0.02) x 103

(2.02 ± 0.02) x 103

Table 1. Accuracy and precision of decitabine, dC, 5mdC and dG calibrators over six validation batches
in digestion matrix. aEach measured value was calculated based on six measurements from different days.
b%RE = {(measured [analyte] — nominal [analyte])/nominal [analyte]} x 100%. cCV = (standard deviation/
mean value) x 100%.

Intra-assaya
Analyte

Nominal
[QC] (nM)

3.00 (LQC)
Decitabine

70.0 (MQC)
1.60 x 103
(HQC)

dC

%RE

CV

3.2 ± 0.1

5

3

71 ± 2

3

2

—2

1

(1.57 ± 0.02) x 103

[Measured
QC ± SD] (nM)

%RE

CV

3.2 ± 0.1

6

4

71 ± 1

3

2

—2

2

1.56 ± 0.01) x 103

3.00 (LQC)

2.9 ± 0.1

—2

4

2.9 ± 0.2

—1

6

69 ± 3

2

4

72 ± 2

4

3

2

1

3

2

(1.63 ± 0.02) x 103

(1.65 ± 0.02) x 103

3.00 (LQC)

3.1 ± 0.1

5

4

3.2 ± 0.3

6

8

70.0 (MQC)

71 ± 4

2

6

72 ± 3

3

4

—1

1

—1

1

1.60 x 103
(HQC)

dG

Inter-assayb

70.0 (MQC)
1.60 x 103
(HQC)

5mdC

[Measured
QC ± SD] (nM)

(1.58 ± 0.02) x 103

(1.58 ± 0.02) x 103

3.00 (LQC)

3.2 ± 0.1

6

4

3.1 ± 0.2

3

6

70.0 (MQC)

66 ± 3

—5

4

67 ± 2

—3

3

1

1

1

2

1.60 x 103
(HQC)

(1.61 ± 0.02) x 103

(1.61 ± 0.02) x 103

Table 2. Intra- and inter-assay precision and accuracy. aIntra-assay precision and accuracy were assessed by
five replicate measurements of individual QC at each concentration. bInter-assay precision and accuracy were
assessed by five parallel measurements of five identical QCs at each concentration.

The studies of matrix effect and analyte recovery on all analytes were conducted using mixed QC at three
concentrations (Table 3). For all analytes, the absolute matrix factors ranged 0.933-1.03 and the IS normalized
matrix factors ranged 0.955-1.03; and the absolute recoveries ranged 90.3-100% and the IS normalized recoveries
ranged 96-102%. These data indicated there was neither significant matrix effect from enzyme digestion buffer
nor significant difference in recoveries of analytes between enzyme digestion buffer and the mobile phase of LC
separation, and the preparation of mixed calibrators of decitabine, dC, dG and 5mdC in either enzyme digestion
buffer or the LC mobile phase makes no difference in the analytical results. Therefore, the mixed calibrators of dC,
dG and 5mdC prepared in the mobile phase were adopted for the method.

Decitabine incorporation vs. hypomethylation of DNA in leukemia cell lines. The LC-MS/MS
method developed was first tested by human leukemia cell lines HL-60 and U937 for quantitation of decitabine
incorporation in cellular DNA and cell responsiveness to decitabine treatment (i.e., decrease of DNA methylation
or DNA hypomethylation). In this study, the effects of drug dose (0.000, 0.100, 0.500, 1.00 and 10.0 µM decitabine) and treatment times (24- and 48-h incubation) were investigated. The cellular DNAs were isolated from
samples of each dose and time point. The enzyme-released decitabine, dC, dG and 5mdC from the cellular DNA
were determined by the method developed and percent methylations were calculated.
As shown in Fig. 5 and summarized in Table 4, the amounts of decitabine incorporated in HL-60 and U937
DNAs were directly proportional to the drug dose and the treatment time. The higher dose and the longer treatment time produced larger amounts of decitabine incorporation in DNA and greater degree of DNA hypomethylation. Also, HL-60 cells have greater viability than U937 cells. This was revealed by the DNA extracted from
each of the cell lines after 24-h and 48-h treatment with decitabine. On average, the amounts of DNA produced
by HL-60 cells were 1.3 and 2.0 times higher than those of U937 cells after 24-h and 48-h treatment with decitabine. Therefore, HL-60 cells showed more sensitivity to the drug treatment in comparison to U937 with larger
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[dC] (nM)

[Decitabine] (nM)

3.00 (LQC)

70.0 (MQC)

1.60 X 103
(HQC)

3.00 (LQC)

[5mdC] (nM)

70.0 (MQC)

1.60 X 103
(HQC)

3.00 (LQC)

[dG] (nM)

70.0 (MQC)

1.60 X 103
(HQC)

3.00 (LQC)

70.0 (MQC)

1.60 X 103
(HQC)

0.959 ± 0.001 0.972 ± 0.001

1.01 ± 0.00 0.964 ± 0.002 0.976 ± 0.002

1.01 ± 0.03

0.933 ± 0.003 0.951 ± 0.006

0.968 ± 0.003

0.943 ± 0.003 0.961 ± 0.007

0.990 ± 0.002

0.977 ± 0.002 0.981 ± 0.001

0.98 ± 0.01

0.977 ± 0.002 0.981 ± 0.001

0.98 ± 0.01

0.977 ± 0.002 0.981 ± 0.001

0.98 ± 0.01

0.977 ± 0.002 0.981 ± 0.001

0.98 ± 0.01

IS Normalized
0.982 ± 0.002 0.991 ± 0.001
MFc ± SD

1.03 ± 0.01

0.987 ± 0.003 0.995 ± 0.002

1.03 ± 0.03

0.955 ± 0.004 0.970 ± 0.006 0.988 ± 0.01

0.965 ± 0.004 0.980 ± 0.007

1.01 ± 0.01

M

± SD

MFISb ± SD

± SD

91.2 ± 0.2

97 ± 1

100 ± 1

92.6 ± 0.3

98 ± 2

100 ± 2

90.3 ± 0.4

95. ± 3

98 ± 1

90.7 ± 0.5

96 ± 4

99 ± 1

Ris6 ± SD (%)

91 ± 2

99 ± 3

99 ± 2

91 ± 2

99 ± 3

99 ± 2

91 ± 2

99 ± 3

99 ± 2

91 ± 2

99 ± 3

99 ± 2

IS Normalized
Rf ± SD

1.00 ± 0.02

0.98 ± 0.03

1.01 ± 0.02

1.02 ± 0.0

0.99 ± 0.04

1.01 ± 0.03

0.99 ± 0.02

0.96 ± 0.04

0.99 ± 0.02

1.00 ± 0.02

0.97 ± 0.05

1.00 ± 0.02

(%)

Table 3. Matrix effect and recovery of decitabine from enzyme digestion matrix (n = 5). aMFAna = (mean
peak area of analyte in extracted enzyme digestion matrix)/(mean peak area of analyte in the mobile phase).
bMFIS = (mean peak area of IS in extracted enzyme digestion matrix)/(mean peak area of IS in the mobile
phase). cIS Normalized MF = MFAna/MFIS. dRAna = [(mean peak area of analyte in enzyme digestion matrix)/
(mean peak area of analyte in extracted enzyme digestion matrix)] x 100%. eRIS = [(mean peak area of IS
in enzyme digestion matrix)/(mean peak area of IS in extracted enzyme digestion matrix)] x 100%. fIS
Normalized R = (RAna/RIS) x 100%. Note: IS 2'-Deoxycytidine 15N3 added at a concentration of 200 nM.

Figure 5. Decitabine incorporation correlates with DNA demethylation in HL-60 and U-937 cells. (A) 24-h
treatment, and (B) 48-h treatment. Experimental conditions were described in “In vitro study” under the
section of “Materials and Methods”.

decitabine incorporation and greater degree of DNA hypomehtylation, which suggested that for U937 cell line,
it may need higher decitabine exposure (either dose or time) than HL-60 cell line to reach the same drug effect.
Decitabine incorporation and hypomethylation effect in a different human leukemia cell line MOLM-13 were
also investigated using both a single dose of decitabine (0.500 µM) for the treatment group and an equal volume
of vehicle (PBS 1X, pH 7.4) for the control group at various time points (0, 4, 8, and 24 h). As shown in Fig. 6, the
profiles of drug effect in the cell line could be monitored by the time course, and the maximum amount of drug
incorporation and hypomethylation effect were observed at 8 h in MOLM-13 cells.

Decitabine incorporation vs. hypomethylation of DNA in animal study.

The method developed
was further tested by analysis of DNA extracted from bone marrow of NSG mice inoculated with human primary

Scientific RepoRts |

(2019) 9:4558 | https://doi.org/10.1038/s41598-019-41070-y

6

www.nature.com/scientificreports/

24-h Study

48-h Study

Decitabine incorporation
(fmol/mg DNA)

Decitabine dose
(µM)
HL-60

U937

DNA methylation

Decitabine incorporation
(fmol/mg DNA)

DNA methylation

HL-60

U937

HL-60

U937

HL-60

U937

4.86

4.89

0.000

0.000

4.86

4.89

0.000

0.000

0.100

88.0

46.0

4.21

4.47

96.0

65.0

4.10

4.23

0.500

120

64.0

3.66

4.16

132

95.0

3.45

3.99

1.00

133

94.0

3.16

3.45

155

114

2.77

3.06

10.0

136

96.0

2.88

3.25

172

146

2.04

2.70

0.000

Table 4. The effects of decitabine dosage and treatment time on decitabine incorporation in DNA and DNA
hypomethylation.

Figure 6. Time course study of decitabine incorporation and DNA demethylation in MOLM-13 cells. (A)
Decitabine incorporation profiles, and (B) DNA demethylation profiles. Experimental conditions were
described in “In vitro study” under the section of “Materials and Methods”.

AML cells for quantitative measurement of DNA-incorporated decitabine and DNA hypomethylation. The experimental details were described in “In vivo animal study” section under “Materials and Methods”. As shown in
Fig. 7A, decitabine incorporation in bone marrow cells from four genetically identical mice after the drug treatment ranged 18.4 to 25.9 fmol per µg DNA, and such treatment significantly reduced DNA methylation in all
mice (P = 0.006, t-test) (Fig. 7B). We had previously reported the efficacy of this treatment in reducing leukemia
burden17,18.

Decitabine incorporation vs. hypomethylation of DNA in clinical study. Finally, the method
developed was applied to PBMCs isolated from peripheral blood obtained from five MDS patients before and
after six weeks of decitabine treatment by a very low dose (0.2 mg/kg) subcutaneous regimen administered twice
per week2. The experimental details were described in “Clinical study” section under “Materials and Methods”.
Among the five patients, four responded well to the decitabine therapy, and one did not. The molecular mechanism of decitabine action and drug resistance in these patients would be depicted by Fig. 8. For patients #1 to #4
who were sensitive to decitabine treatment, decitabine incorporation and DNA hypomethylation were large and
significant (P = 0.07, t-test) (Fig. 8A,B); whereas for patient #5 who was resistant to the drug, there were minimum decitabine incorporation (Fig. 8C), and even higher DNA methylation in posttreatment (Fig. 8D).
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Figure 7. Decitabine incorporation and DNA demethylation in vivo animal study. (A) Decitabine
incorporation in the controls and decitabine-treated mice (n = 4), and (B) DNA demethylation in the controls
and decitabine-treated mice. Experimental conditions were described in “In vivo animal study” under the
section of “Materials and Methods”.

Discussion
Target engagement is necessary for any drug to work, and the measurement of target engagement of decitabine
(i.e., decitabine incorporation and DNA hypomethylation) is the first step to understand patients' sensitivity
and resistance in decitabine therapy; however, a practical method for this purpose was lacking. The method we
developed is practical, very sensitive and specific for measurement of decitabine, 5mdC, and dG, as no interferences from endogenous molecules were observed. Furthermore, this method has been fully validated in enzyme
digestion matrix and essentially met the validation criteria established by US-FDA. Such method may help us not
only to understand drug action and resistance mechanisms of decitabine, but also to design more effective dosing
regimens for patients.
In the in vitro dose and time course studies, no cell death was observed with the treatment doses and durations
used. Decitabine incorporation into DNA of HL-60 and U937 was both dose and time dependent, and notably,
uptake via passive nucleoside transporters 1 (ENT1)19 is drug concentration-dependent. Although decitabine
triphosphate incorporation into DNA by DNA polymerase occurs only during S-phase20, the drug incorporation
in the in vitro studies was around-the-clock because cycling by the cells was unsynchronized. In the time course
study of decitabine incorporation in DNA of MOLM-13 cells (Fig. 6), the decitabine incorporation profile deviated from the steady-state profile, likely because of decomposition of decitabine in cell culture medium (decitabine has an in vitro half-life of 5-16 hours at 37 °C)21.
Different responses to decitabine treatments in in vitro and in vivo may be a consequence of differences in
expression of key pyrimidine metabolism enzymes in different tissues and different models17,18. DCK performs
the initial phosphorylation of decitabine and rate-limits the conversion of decitabine to decitabine triphosphate.
CDA and DCTD metabolize decitabine and, decitabine mono-phosphates into non-DNMT1-depleting uridine
derivatives. In the case of the patient with the myeloid malignancy that did not respond to decitabine, decitabine
triphosphate incorporation into DNA was about 9% (3 fmol/µg DNA) in comparison to ~10-fold greater incorporation in the patients with disease that did respond to treatment (33 ± 11 fmol/µg DNA); furthermore, in the
patient with unresponsive disease, DNA hypomethylation was not observed. Instead DNA methylation increased
from 4.22% (pretreatment) to 5.60% (posttreatment)3,8.
Previous attempts at correlating DNA hypomethylation in peripheral blood cells with response to decitabine
treatment have had mixed results22-24 One difference is that these previous studies administered decitabine by
standard pulse-cycled regimens, and DNA methylation changes may therefore have been more substantially
influenced by the timing between peripheral blood collection and drug administration. By contrast, the patients
analyzed in this study received decitabine twice weekly continuously for 6 weeks prior to the peripheral blood
sample collection. A limitation of our study and on our conclusions remains the small number of clinical samples
analyzed.
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Figure 8. Decitabine incorporation and DNA demethylation in clinical study. (A) Decitabine incorporation
in AML patients who were sensitive to decitabine treatment (n = 4), (B) DNA demethylation in AML patients
who responded to decitabine treatment (n = 4) (P = 0.07, t-test), (C) Decitabine incorporation in AML patient
who did not respond to decitabine treatment, and D) DNA demethylation in AML patient who did not respond
to decitabine treatment. Experimental conditions were described in “Clinical study” under the section of
“Materials and Methods”.

In sum, quantitative measurement of decitabine incorporation rates and DNA hypomethylation effects can
potentially determine early time points where patients with disease are non-responsive to their decitabine dosing
regimens, and guide dosage adjustment or selection of alternative therapies. In other words, since the molecular
pharmacodynamic intention with decitabine therapy is its incorporation into DNA, it may be useful to prospectively evaluate if the method for measurement of this pharmacodynamic effect that we describe here can guide
individualization and optimization of therapy in patients with myeloid malignancies.

Materials and Methods
Chemicals.

Decitabine was obtained from Developmental Therapeutics Program of the National Cancer
Institute (Bethesda, MD, USA). Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (BIS-TRIS), deoxyribonuclease I type II (DNase I), nuclease P1 (NP1), bovine alkaline phosphatase (ALP), 2'-deoxycytidine (dC),
2'-deoxyguanosine (dG), 2'-deoxythymidime (dT), 2'-deoxyadenosine (dA) and formic acid were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Snake venom phosphodiesterase I (PDE I) was obtained from Worthington
Biochemical (Lakewood, NJ, USA). 2'-Deoxycytidine 15N3 (96-98%, a stable heavy isotope of 2'-deoxycytidine)
was purchased from Synthèse AptoChem (Montreal, Quebec, Canada). 5-methyl-2'-deoxycytidine (5mdC) was
purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Sodium chloride, zinc chloride, phosphate buffered saline (PBS, 10X, pH 7.4), phenol saturated with Tris buffer (pH 6.6), HPLC-grade of methanol, acetonitrile
and chloroform were purchased from Fisher Scientific (Fair Lawn, NJ, USA). 10% sodium dodecyl sulfate (SDS)
solution was obtained from Bio-Rad Laboratories (Hercules, CA, USA). RPMI-1640 medium with L-glutamine
was purchased from Mediatech (Manassas, VA, USA). Fetal bovine serum was purchased from GE Healthcare
Life Sciences (Logan, UT, US). RiboShredder™ RNase Blend was purchased from Epicentre (Madison, WI, USA).
Proteinase K was ordered from Qiagen (Valencia, CA, USA).

In vitro studies.

Cell lines HL-60 and U937 were obtained from American Type Culture Collection
(Rockville, MD, USA). MOLM-13 cell line was obtained from Leibniz Institute DSMZ - German Collection
of Microorganisms and Cell Cultures (Braunschweig, Germany). HL-60, U937 and MOLM-13 cell lines were
cultured in RPMI-1640 medium supplemented with L-glutamine, 1% Penicillin-Streptomycin and 10% (v/v)
fetal bovine serum in a humidified 5% CO2 incubator at 37 °C. Decitabine solution was freshly prepared for each
experiment by dissolving decitabine powder in PBS (1X, pH 7.4) at a concentration of 1.00 mM.
For each 1 x 106 cells of HL-60 and U937 cell lines, the dosages of decitabine added to the culture media are
0.00, 0.100, 0.500, 1.00, or 10.0 p,M; and were treated for 24 h and 48 h at 37 °C in a humidified 5% CO2 incubator.
MOLM-13 cells (1 x 106 cells) was treated with 0.500 µM of decitabine or an equal volume of PBS (1X, pH 7.4)
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as control for 0, 4, 8, and 24 h at 37 °C in a humidified 5% CO2 incubator. After treatment, the cells were removed
from the medium by centrifugation at 1,500 x g, 4 °C for 5 min; and washed twice with 5.00 mL of PBS (1X, pH
7.4) each. The cell pellets were collected and stored in -20 °C until DNA extraction.

In vivo animal study. The animal study for this work was approved by the Cleveland Clinic Institutional
Animal Care and Use Committees (IACUC) and all methods were performed in accordance with the relevant
guidelines and regulations. NSG mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Primary
acute myelogenous leukemia (AML) cells from patients were transplanted by tail-vein injection (0.4 x 106 cells/
mouse) into non-irradiated 6-8 week old NSG mice (n = 4 per/group). Mice were anesthetized with isoflurane before transplantation. On day 15 of inoculation, animal groups were treated subcutaneously with vehicle
(PBS 1X, pH 7.4) or decitabine 0.100 mg/kg for three consecutive days per week during the course of study. The
control-group animals (median survival of 45 days) were euthanized by an IACUC approved method for signs of
distress, and the treatment-group animals were continued with treatment for 90 days. At 90 day of the treatment,
animals were euthanized by the IACUC approved method.
DNA was extracted from bone marrow using the procedure published in the ref.25. Bone marrow cells were
washed twice with 10.0 mL PBS (1X, pH 7.4) each. In each wash step, the cells were gently vortexed in PBS (1X,
pH 7.4) for 1 min and then centrifuged down at 1,500 x g, 4 °C, for 10 min. After washing, the cell pellet was frozen at -20 °C until DNA extraction.

Clinical study.

The five MDS patients of this study were enrolled in the clinical trial (NCT01165996) with
written informed consent on a protocol approved by the Institutional Review Board of Taussig Cancer Institute
at the Cleveland Clinic and all methods were performed in accordance with the relevant guidelines and regulations. The patients analyzed had MDS sub-types chronic myelomonocytic leukemia (CMML, n = 3) and refractory cytopenia with multi-lineage dysplasia (RCMD, n = 2). The decitabine regimen was 0.2 mg/kg administered
subcutaneously two consecutive days per week with the post-treatment samples obtained after six weeks of this
treatment. 10.0 mL of peripheral blood samples were collected from each patient in heparinized BD Vacutainer®
tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) before and at the end of 6th week of treatment.
The blood samples were fractioned by the Ficoll-Paque method26. Briefly, 10.0 mL heparinized blood was layered
on the top of 12.0 mL Ficoll-Paque Plus reagent (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) in a 50.0-mL
sterile polypropylene centrifuge tube (RNase/DNase free); then the tube was centrifuged at 300 x g, 4 °C, for
20 min. The peripheral blood mononuclear cells (PBMCs) at the interface between plasma and polymorphonuclear cells were collected and transferred into a clean 15.0-mL centrifuge tube and washed twice with 10.0 mL
PBS (1X, pH 7.4) each. In each wash step, the PBMCs were gently vortexed in PBS (1X, pH 7.4) for 1 min and
then centrifuged down at 4 °C and 1,500 x g for 10 min. After washing, the cell pellet was collected and stored in
-20 °C until DNA extraction.

DNA isolation and hydrolysis.

Each cell pellet collected from the in vitro, in vivo and clinical studies was
lysed by mixing gently with 2.00 mL of TE buffer (containing 10.0 mM Tris and 1.00 mM EDTA at pH 8.0) and
240 µL of 10% SDS solution for 2 min. Then, the lysate was incubated with 25.0 µL of proteinase K (600 mAU/
mL) for 1 h at 37 °C. After the incubation, the sample solution was transferred to a phase lock gel tube (5 Prime,
Gaithersburg, MD, USA), and DNA was extracted using standard phenol/chloroform extraction method27. The
DNA extracted was dissolved in 5.00 mM BIS-TRIS buffer (pH 7.0) to a concentration of 1.00 mg/mL measured
by UV spectrophotometry. The co-extracted RNA was removed by adding 2.00 µL of RiboShredder™ RNase
Blend (1 U/µL) to each 100 µL of DNA sample (1.00 mg/mL). After a 30-min incubation at 37 °C, the sample was
mixed with 1.00 mL of pre-chilled ethanol (-20 °C) and kept at -20 °C for overnight to precipitate the DNA in
the sample. After centrifugation at 15,000 x g for 15 min, the supernatant was discarded, and the DNA pellet was
washed with 1.00 mL of pre-cooled 70% ethanol (-20 °C) twice. Then, the DNA pellet was air-dried and reconstituted with 100 µL of 5.00 mM BIS-TRIS buffer (pH 7.0) for subsequent enzyme digestion.
DNA hydrolysis was performed by denaturing ds-DNA to ss-DNA in boiling water for 30 min followed by a
one-step tetra-enzyme digestion15,28. The tetra-enzyme cocktail was prepared by mixing the enzyme solutions as
follows: 10.0 µL of DNase I (20,000 U/mL), 15.0 µL of NP1 (200 U/mL), 40.0 µL of PDE I (100 U/mL) and 0.50 µL
of ALP (40,000 U/mL). For each 50.0 µL of DNA (0.500 µg/µL for the measurement of DNA incorporated decitabine; 1.25 ng/µL for the measurements of dC, dG, and 5mdC), 4.00 µL of the tetra-enzyme cocktail was added
and mixed well; then, the mixture was placed in a 37 °C water bath for overnight incubation to secure a complete
digestion of DNA to mononucleosides. After incubation, 5.00 µL of 2'-deoxycytidine 15N3 (the internal standard,
IS, 2.00 µM in the LC mobile phase) was added to a digested sample and vortex-mixed for 30 s. Each DNA digest
was deproteinized by 450 µL of acetonitrile, then centrifuged at 15,000 x g for 10 min. 450 µL of supernatant was
collected and evaporated to dryness at 30 °C for 60 min in a TurboVap® LV Evaporator (Zymark, Hopkinton, MA,
USA) under a pressurized stream of nitrogen gas (20 psi). The dried residue was reconstituted in 50.0 µL of the LC
mobile phase and subjected to LC-MS/MS analysis.

LC-Ms/Ms system.

The LC-MS/MS instrumentation used for this work consisted of a Prominence UFLC
system (Shimadzu, Columbia, MD, USA) for analyte separation and a QTRAP 5500 tandem mass spectrometer
(AB Sciex, Foster City, CA, USA) for quantitation. The system was controlled by AB Sciex Analyst® software
(version 1.6.1) for its operation, data acquisition, and processing. The UFLC system included a system controller
(CBM-20A), two binary pumps (LC-20AD), a temperature-controlled autosampler (SIL 20AHT) and an online
degasser (DGU20A3).

Quantitation of decitabine, dG, dC, and 5mdC. The LC separation was carried out on a Hypersil Gold
aQ C18 column (50 x 2.1 mm, 3 um) (Thermo Scientific, Waltham, MA, USA) with a Hypersil Gold aQ C18
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guard column (10 x 2.1 mm, 3 µm) using the LC mobile phase consisting of 0.1% formic acid aqueous solution
and methanol (87.5:12.5, v/v) at a flow rate of0.300 mL/min. For each analysis, 10.0 µL of sample was injected into
the system by autosampler set at 4 °C. The LC elute was introduced into the mass spectrometer operated under the
positive turbo-ion spray ionization mode. The optimized instrument parameters were as follows: curtain (CUR),
40 psi; collision activated dissociation (CAD) gas, medium; nebulizer gas (GS1), 40 psi; turbo heater gas (GS2),
45 psi; turbo ion spray voltage (IS), +5200 V; source temperature (TEM), 300 °C; declustering potential (DP),
35 V; entrance potential (EP), 7 V; collision energy (CE), 15 V; collision cell exit potential (CXP), 18 V; mass resolutions (Q1 and Q3), 1 unit. The multiple-reaction-monitoring (MRM) mode was used for analyte quantitation.
Mixed calibrators of decitabine, dC, dG and 5mdC (1.00, 4.00, 20.0, 40.0, 200, 400 and 2.00 x 103 nM) together
with single- and double- blanks, and mixed QCs (3.00, 70.0 and 1.60 x 103 nM) were prepared in 5.00 mM
BIS-TRIS buffer (pH 7.0) and subjected to the same sample preparation procedure as DNA samples. The linear
calibration plots for decitabine, dC, dG, and 5mdC were constructed using peak area ratios (y) of each analyte
to the IS versus the concentrations of calibrators (x) with 1/x weighting, and the least squares linear regression
equations were obtained as the calibration equations for individual analytes.
The concentrations of decitabine, dC, dG, and 5mdC in each unknown sample were back calculated by the
calibration equations using the peak-area ratios of each analyte in the unknown sample to that of the IS. The
accurate mass concentration of DNA was determined using the measured molar concentration of dG by the
following equation:
[DNA](mg/L) = [dG] x618 (g/mol)/0.41

(1)

where [dG] is the measured concentration of dG in mM; 618 (g/mol) is the molar mass of G/C pair, and 0.41 is the
percentage of G/C pair in human DNA29. The amount of DNA incorporated decitabine was expressed as pmol of
decitabine per µg of DNA. The percent methylation was calculated using the following equation29-31:
%methylation = [5mdC/(dC + 5mdC)] x 100%

statistical analysis.

(2)

Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software Inc.,

San Diego, CA).

Conclusion
We have developed a sensitive and specific LC-MS/MS method for quantitative determination of decitabine DNA
incorporation and hypomethylation effect both in vitro and in vivo. This method is practical and can be easily adopted in preclinical and clinical studies of decitabine. The preliminary data from decitabine-treated AML
patients show that this method not only allows us to quantitatively measure the pharmacokinetic endpoints of
decitabine but also provides supporting evidence for drug action mechanisms on patients' sensitivity and resistance in decitabine therapy. It may be useful for determining suitable decitabine dosing regimens for individual
patients to achieve desirable therapy outcomes.
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